U.S. Markets closed

Galena Bio's NeuVax improves disease-free survival at 60-month median follow-up

Galena Biopharma updated NeuVax, or E75, results at a physician panel on today during the American Society of Clinical Oncology, or ASCO, 2012 Annual Meeting in Chicago, Illinois. The combines Phase 1/2 NeuVax clinical trials, SN-33 node positive, and SN-34 node negative, continue to demonstrate an excellent safety and efficacy profile at median 60-month follow-up.